Company intelligence / Profile preview

Celosia Therapeutics

Macquarie Park, New South Wales, Australiacelosiatx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Celosia Therapeutics is developing CTx1000, a novel gene therapy targeting TDP-43 protein for ALS. The groundbreaking discovery was published in the journal Neuron in February 2024. The company is advancing toward clinical trials after securing significant Series A funding.

Therapeutic areas: Neurology
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

4 assets

CTx1000

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Celosia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celosia Therapeutics.

Explore the full profile